key: cord-0984741-rhm3c8ra
authors: Friedli, Christoph; Diem, Lara; Hammer, Helly; Kamber, Nicole; Suter-Riniker, Franziska; Leib, Stephen; Chan, Andrew; Hirzel, Cédric; Hoepner, Robert; Salmen, Anke
title: Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies
date: 2021-05-18
journal: Ther Adv Neurol Disord
DOI: 10.1177/17562864211016641
sha: bcbec30d46917d4fc0def32f3641c3c70ed28155
doc_id: 984741
cord_uid: rhm3c8ra

nan

We report eight patients from our tertiary care neurologic outpatient department treated with anti-CD20 therapies, of which six showed negative SARS-CoV2-antibodies [cut-off value for negative tests/assay: anti-nucleocapsid IgG 1.4 Index Alinity (Abbott, Abbott Park, IL, USA); anti-spike protein IgG 12.0 AU/ml; Liaison SARS-CoV-2 S1/S2 IgG (DiaSorin, Saluggia, Italy)] after a symptomatic infection with positive COVID-19 PCR nasopharyngeal swab. The remaining two patients had a strong positive response for anti-spike protein IgG (64.6 AU/ml) with negative anti-nucleocapsid IgG or a weak positive response for anti-spike protein IgG (29.3 AU/ml) and positive anti-nucleocapsid IgG (2.9 Index), respectively.

Six of these patients were treated with ocrelizumab [n = 5 with relapsing remitting (RR) multiple sclerosis (MS), n = 1 with primary progressive (PP) MS]. Two patients were treated with rituximab, one each for neuromyelitis optica spectrum disorder (NMOSD) and active secondary progressive (aSP) MS, respectively. Mean interval between last anti-CD20-infusion to positive COVID-19-PCR nasopharyngeal swab was 4.9 months (range 3-10 months); mean interval from positive COVID-19-PCR nasopharyngeal swab to SARS-CoV2-antibody testing was 3.8 months [range 1-9 month(s)]. Six patients were female, mean age was 51.1 years (range 37-69 years), mean disease duration was 7.8 years [range 1-16 year(s)] and mean expanded disability status scale (EDSS) was 3.1 (range 1.5-4.5). Four patients with COVID-19 were managed in an ambulatory setting, whereas four of our patients had a COVID-19infection warranting hospitalisation, but none needed respiratory support. For further patients characteristics, see Table 1 . All of the patients included in our case series signed an informed consent, which includes the publication of the medical data in an anonymised form and this work is in accordance with the regulations of our local ethical committee.

In accordance with other case reports, 1,2 these data highlight that patients treated with anti-CD20therapies may lack an antibody response after symptomatic COVID-19. Our findings are in line with other case reports, but in our study we tested for several epitopes (anti-nucleocapsid IgG and anti-spike protein), whereas in previous case reports, only single epitopes were measured. Usually, a detectable anti-spike and anti-nucleocapsid IgG antibody response to SARS-CoV2 is present within few days after symptom onset. 3 The initial antiviral responses are driven mainly by T-cells, in particular CD8+ cytotoxic T-lymphocytes, and natural killer cells and less by B-cells, which may explain why patients on anti-CD20 therapies cope relatively well with viral infections. So far, it is uncertain to what extent COVID-19 results in a long-lasting immunity, but it is generally accepted that neutralising antibodies play a crucial role in protection against coronaviruses. 4 Therefore, the finding of a lacking antibody response after a symptomatic COVID-19 in patients treated with anti-CD20-therapies may imply an increased risk for re-infection. In addition, anti-CD20-therapies may lead to an absent antibody response to SARS-CoV2-vaccines, as has been predicted by Baker et al. 5 In our opinion, this should prompt closer surveillance including monitoring of the immune response in patients treated with anti-CD20-therapies after both infection and vaccination, in order to clarify whether these individuals remain at risk for SARS-CoV-2 infection. If vaccination or infection fails to protect a high proportion of patients on anti-CD20 therapy, the safekeeping of these vulnerable individuals Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies DMT, disease modifying treatment; EDSS, expanded disability status scale; NMOSD, neuromyelitis optica spectrum disorder; OCR, ocrelizumab; PPMS, primary progressive multiple sclerosis; RTX, rituximab; SARS-CoV-2, severe acute respiratory syndrome corona virus 2; RRMS, relapsing remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.

Beyond COVID-19: do MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?

COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies

Magnitude and kinetics of anti-severe acute respiratory syndrome coronavirus 2 antibody responses and their relationship to disease severity

Vaccines for SARS-CoV-2: lessons from other coronavirus strains

COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases

Visit SAGE journals online journals.sagepub.com/ home/tan

journals.sagepub.com/home/tan 3 will depend on herd immunity and individual protective measures such as physical distancing and following hygiene rules.

The authors declare that there is no conflict of interest.

The authors received no financial support for the research, authorship, and/or publication of this article.